PlnA Bacteriocin Agent for Rotavirus NSP4 Calcium Disruption

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack a specific pharmaceutical agent to prevent and eliminate the adverse effects of the rotavirus NSP4 viral protein, particularly in cells and organisms, and there are challenges in production, supply, distribution, and therapeutic efficacy.

Innovation Solution

A pharmaceutical agent containing Lactobacillus plantarum bacteriocin PlnA is developed to reduce intracellular calcium levels and increase anti-inflammatory cytokine IL-10 levels, thereby preventing and eliminating the adverse effects of the rotavirus NSP4 protein.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If non-specific antiviral drugs and fluid supplements are used to treat rotavirus infections, then symptom alleviation is achieved, but there is no specific method to prevent adverse effects caused by NSP4 protein

Engineering Contradiction:

Improveadverse effects of NSP4 proteinVSAvoidspecific pharmaceutical agent

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

The patent introduces PlnA bacteriocin as an intermediary substance that specifically targets and neutralizes the NSP4 protein. PlnA acts as a mediator between the host cell and the viral protein, binding to NSP4 and preventing its harmful effects on cellular calcium homeostasis and membrane permeability, thereby resolving the lack of specific treatment options.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biochemical parameter of cellular calcium concentration by introducing PlnA, which restores normal calcium homeostasis disrupted by NSP4. The bacteriocin modifies the intracellular calcium level parameter, preventing the excessive calcium influx that leads to cell death and adverse effects, thus providing specific protection against NSP4 toxicity.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If vaccines are distributed to countries with high rotavirus disease rates, then immunization is provided, but distribution is inadequate and effectiveness is low in developing countries

Engineering Contradiction:

Improvevaccine effectivenessVSAvoidvaccine distribution

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent proposes PlnA bacteriocin as a cost-effective, easily deployable intervention that can be administered through simple oral formulations. Unlike complex vaccines requiring cold chains and specialized distribution infrastructure, PlnA can be delivered through basic healthcare systems or even community-based programs, making it suitable for resource-limited settings in developing countries.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Productivity

If calcium concentration is increased to 10 mM in the diet, then rotavirus replication is promoted, but this increases the likelihood of infection and spread

Engineering Contradiction:

Improveviral replicationVSAvoidinfection likelihood

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of high calcium concentration (which promotes viral replication) into a beneficial target for treatment. By identifying that 10 mM calcium creates favorable conditions for rotavirus, the invention uses PlnA to specifically counteract this parameter, thereby transforming the understanding of calcium's role from purely harmful to a targetable factor that can be modulated for therapeutic benefit.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The agent effectively reduces intracellular calcium levels and enhances IL-10 expression to inhibit inflammation and viral replication, offering improved protection and treatment efficacy with reduced costs.

Implementation Method 1

NSP4 protein significantly increases cytosolic calcium through different mechanisms, including a Phospholipase C (PLC)-dependent mechanism associated with the enterotoxin properties of this protein. However, the most important mechanism is ER degradation mediated by the viroporin properties of this protein and the subsequent increase in cytoplasmic Ca+2 concentration.

Methodology Applied

Scientific EffectCalcium homeostasis regulation:

Implementation Method 2

IL-10, as an anti-inflammatory cytokine, may have strong anti-inflammatory effects and IL-10 is also known to play an important role in enteric infections and intestinal inflammation

Methodology Applied

Scientific EffectCytokine production:

Data Source

PatentUS20250352612A1Pharmaceutical agent to prevent the adverse effects of rotavirus NSP4 protein

Publication Date: 2025.11.20 AFYONKARAHISAR SAGLIK BILIMLERI ÜNIVERSITESI REKTÖRLÜGÜ

AI summary

Disclosed is a pharmaceutical agent for the prevention and/or elimination of the adverse effects of the rotavirus NSP4 viral protene in cells and/or organisms using the Lactobacillus plantarum bacteriocin PlnA.